

# Quarter 1 2015 & 2014



... igniting new medical, consumer and technology ideas with capital

# **Table of Contents**

Statements of Assets and Liabilities as of March 31, 2015 and 2014	3
Statements of Operations for the Quarter ended March 31, 2015 and 2014	4
Statements of Changes in Net Assets for the Quarter Ended March 31, 2015 and 2014	.5
Statements of Cash Flows for the Quarters Ended March 31, 2015 and 2014	6
Schedule of Investments	7
Notes to the Financial Statements	.8

#### Statements of Assets and Liabilities

	Period Ended March 31	
	2015	2014
ASSETS		
Cash and cash equivalents	\$56,544	\$236,335
Interest receivable	400	-
Investments, at fair value		
Non-controlled/non-affiliate company investments	329,000	457,500
Total investments, at fair value	329,000	457,500
TOTAL ASSETS	385,944	693,836
LIABILITIES		
Debt	0	29,157
Accounts payable and accrued expenses	2,000	0
TOTAL LIABILITIES	\$2,000	\$29,157
NET ASSETS		
Preferred stock, par value \$0.001 per share, 80,000,000 shares authorized, zero shares issued and outstanding as of		
September 30, 2014 and September 30, 2013	\$0	\$0
Common stock, par value \$0.001 per share, 700 million shares authorized, 75,307,167 and 75,181,167 shares issued and outstanding as of March 31, 2015 and		
March 31, 2014, respectively	75,307	75,181
Additional Paid-in-Capital	9,751,521	9,575,147
Unexercised Options	-	100,000
Retained Deficit	(9,442,884)	(9,085,649)
TOTAL NET ASSETS	\$383,944	\$664,679
Number of common shares outstanding	75,307,167	75,181,167
Net asset value per common share	\$0.01	\$0.01

# Statements of Operations

	Quarter Ended March 31	
	2015	2014
INVESTMENT INCOME		
From non-controlled non-affiliated investments		
Interest	\$400	\$0
Other Income	0	0
Total Income	400	0
EXPENSES		
Consulting Fees	0	2,600
Legal Services	2,700	3,500
Professional Fees	11,500	22,500
Administrative Services Expense	3,300	2,450
Other General and Administrative Expenses	960	761
Total Expenses	18,460	31,811
NET LOSS	(\$18,060)	(\$31,811)
REALIZED AND UNREALIZED LOSS ON INVESTMENTS AND CASH EQUIVALENTS		
Net realized gain/(loss)		
Net realized gain/ (loss)	0	0
Net change in unrealized depreciation/appreciation		
Net change in unrealized depreciation/appreciation	0	0
Net realized gain/ (loss) from investments & cash equivalents	0	0
NET DECREASE IN NET ASSETS		
RESULTING FROM OPERATIONS	(\$18,060)	(\$31,811)
LOSS PER SHARE- BASIC & DILUTED	(\$0.00)	(\$0.00)

# Statements of Changes in Net Assets

	Quarter ended March 31	
-	2015	2014
Increase (decrease) in net assets from operations:		
Net Loss	(\$18,060)	(\$31,811)
Interest receivable	(400)	-
Accounts payable Net Change in Unrealized Depreciation/Appreciation	(153) 0	- 0
Net Increase (Decrease) in Net Assets Resulting from Operations	(\$18,613)	(\$31,811)
Dividends and Distributions to Stockholders	0	0
Capital Share Transactions:		
Net Proceeds from Shares Sold	\$0	\$50,000
Shares Issued for Investments	0	0
Shares Issued for Services and Settlement of Liabilities	1,500	0
Net Increase in Net Assets from Capital Share Transactions	\$1,500	\$50,000
Total Decrease (Increase) in Net Assets	\$(16,560)	\$36,188
Net Assets at Beginning of Period	402,504	657,647
Net Assets at End of Period	\$385,944	\$693,835
Capital Share Activity		
Shares Sold	0	500,000
Shares cancelled, issued incorrectly	0	0
Shares Issued for Investments	0	0
Shares Issued for Services and Settlement of Liabilities	10,000	0
Net Increase from Capital Share Activity	10,000	500,000

#### **Statements of Cash Flows**

	Quarter ended March 31	
	2015	2014
CASH FLOWS FROM OPERATING ACTIVITIES		
Net loss	(\$18,060)	(\$31,812)
Interest receivable	(400)	-
Accounts payable	(153)	-
Shares issued for services and settlement of liabilities	1,500	-
Net cash used in operating activities	(16,560)	(31,812)
CASH FLOWS FROM FINANCING ACTIVITIES		
Net proceeds from debt	0	0
Net proceeds from issuance of common stock	0	50,000
Net cash provided by financing activities	0	50,000
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	(16,560)	36,188
CASH & CASH EQUIVALENTS, BEGINNING OF PERIOD	73,657	200,147
CASH & CASH EQUIVALENTS, END OF PERIOD	\$56,544	\$236,335

#### Schedule of Investments

INVESTMENTS IN NON-CONTROLLED, NON-AFFILIATED INVESTMENTS	INDUSTRY	COST	FAIR VALUE
COMMON EQUITY/INTERESTS			
Active Faith, Inc.* 61,500 common stock shares @ \$5.00 per share	Retail	\$307,500	\$246,000
Thru Pharma LLC, Member Units** 3 member units @ \$50,000 per unit	Pharma	150,000	75,000
TOTAL COMMON EQUITY/INTERESTS		\$457,500	\$321,000

\* Purchased through issuance of Company stock in the amount of 3,075,000 shares

\*\* Purchased through issuance of Company stock in the amount of 1,500,000 shares

CONVERTIBLE DEBT INVESTMENT	COST	FAIR VALUE
Convertible Promissory Note w ith interest @10% p.a. Signed by Bill Madson. Matures September 12, 2015. Secured by Membership Unit Certificate # 11-152 for 1 (one) unit of Thru Pharma LLC in name of Bill Madson.	<u>\$8.000</u>	<u>\$8,000</u>
TOTAL CONVERTIBLE DEBT INTERESTS	\$ <u>8,000</u>	\$ <u>8,000</u>

#### Notes to Financial Statements

#### Note 1. Organization

Champion Investments, Inc. is an internally managed management investment company that has applied to the SEC to be regulated as a business development company under the Investment Company Act of 1940, as amended, or the 1940 Act.

The Company intends to make investments in US-based early stage, emerging and small to middlemarket enterprises in the technology, medical, life sciences and consumer sectors with revenues or valuations of less than \$25 million.

The Company's investment objective is to generate current income and capital appreciation by investing primarily in talented and proven entrepreneurial managers and firms who are in need of additional financial resources, minority-ownership capital or management expertise to assist them in the continued expansion and successful growth of their businesses.

The investment strategies of Champion Investments, Inc. will focus on the best opportunities for its shareholders in four investment core categories: Micro-Investments, Recapitalizations, Special Growth and Acquisitions. By employing these multiple investment strategies, the Company's model is intended to increase its flexibility to capitalize on opportunistic investments and exits, while mitigating relative risk. The management team of the Company believes these high-impact, relatively lower investment categories are currently underserved by traditional sources of individual and institutional investors.

The Company seeks to create a diverse portfolio that includes secured convertible loans, options, warrants or minority equity securities by primarily investing approximately \$100,000 to \$500,000 of capital, on average, and Company stock in the securities of early stage and emerging companies. The Company may also selectively invest more than these amounts in some of the Company's future portfolio companies and generally expect that the size of the Company's individual investments will vary proportionately with the size of the Company's capital base.

To execute these diversified strategies, the Company has assembled a management team comprised of expertise in early-stage investment funding in medical, technology and retail product organizations and emerging small business marketing and management organizations.

As of March 31, 2015, the Company's portfolio at fair value was comprised of equity investments purchased with common stock of the Company valued at \$.10 per share. Investments were made in a medical products firm, Thru Pharma, LLC. dba pharmaCline, a life science company specializing in pathogen genomics, bioinformatics and therapeutics, and Active Faith, Inc., a consumer sports apparel firm.

As of March 31, 2015, the Company had equity investments in these two portfolio enterprises, respectively with an estimated fair market value of \$321,000 and a Convertible Debt investment in a Promissory Note with a principal amount of \$8,000 that matures September 12, 2015, secured by 1 (one) unit of Thru Pharma LLC membership interest. This investment has an estimated market value of \$8,000.

#### Note 2. Significant Accounting Policies and Recent Accounting Updates

#### Basis of presentation

The accompanying financial statements of the Company and related financial information have been prepared in accordance with U.S. generally accepted accounting principles ("GAAP") and pursuant to the requirements for reporting on Form 10-Q. In the opinion of management, the consolidated financial

statements reflect all adjustments and reclassifications consisting solely of normal accruals that are necessary for the fair presentation of financial results as of and for the periods presented.

#### Fair value of financial instruments

The Company applies fair value to all of its financial instruments. Fair value is a market-based measure considered from the perspective of the market participant who holds the financial instrument rather than an entity specific measure. Therefore, when market assumptions are not readily available, the Company's own assumptions are set to reflect those that management believes market participants would use in pricing the financial instrument at the measurement date. The availability of observable inputs can vary depending on the financial instrument and is affected by a wide variety of factors, including, for example, the type of product, whether the product is new, whether the product is traded on an active exchange or in the secondary market and the current market conditions. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment.

The levels of fair value inputs used to measure our investments are characterized in accordance with the fair value hierarchy established by ASC 820. Where inputs for an asset fall in more than one level in the fair value hierarchy, the investment is classified in its entirety based on the lowest level input that is significant to that investment's fair value measurement. The Company uses judgment and considers factors specific to the investment in determining the significance of an input to a fair value measurement. Our policy is to recognize transfers in and out of levels as of the beginning of each reporting period. The three levels of the fair value hierarchy and investments that fall into each of the levels are described below:

**Level 1:** Level 1 inputs are unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets.

**Level 2:** Level 2 inputs are inputs, other than quoted prices included within Level 1 that are observable for the asset, either directly or indirectly.

Level 3: Level 3 inputs are unobservable and cannot be corroborated by observable market data.

The Company values its current investments in non-publically traded companies based on its knowledge of recent sales in private placement transactions adjusted for factors management feels is appropriate.

Any changes to the valuation methodology are reviewed by management and the Company's Board of Directors (the "Board") to confirm that the changes are appropriate. As markets change, new products develop and the pricing for products becomes more or less transparent, the Company will continue to refine its valuation methodologies.

#### Use of estimates

The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

#### Consolidation

The Company will generally not consolidate its investment in a company other than an investment company subsidiary or a controlled operating company whose business consists of providing services to the Company.

#### Cash and cash equivalents

Cash and cash equivalents are highly liquid investments with an original maturity of three months or less at the date of acquisition. The Company deposits its cash in financial institutions and, at times, such balances could be in excess of the Federal Deposit Insurance Corporation insurance limits.

#### **Revenue recognition**

#### Investments and related investment income

Interest income is accrued by the Company based upon the outstanding principal amount and contractual interest terms of its investments. In addition, the Company may generate revenue in the form of commitment, origination, amendment, structuring or due diligence fees, fees for providing managerial assistance and consulting fees. Original issue discounts and market discounts or premium are capitalized, and the Company accretes or amortizes such amounts over the life of the Ioan as interest income. All other income is recorded into income when earned.

For the quarter ended March 31, 2015 the Company had interest income of \$400, compared to \$0 in the quarter ended March 31, 2014.

Investment transactions are accounted for on a trade-date basis. Realized gains or losses on investments are measured by the difference between the net proceeds from the disposition and the cost basis of investment, without regard to unrealized gains or losses previously recognized. The Company reports current period changes in fair value of investments that are measured at fair value as a component of the net change in unrealized appreciation (depreciation) on investments in the statements of operations.

#### Dividends and distributions

Dividends and distributions to common stockholders are recorded on the record date. The amount to be paid out as a dividend or distribution is determined by the Board of Directors and is based upon the earnings estimated by management.

For the quarter ended March 31, 2015 and 2014, the Company did not pay any dividends or distributions to the common stockholders.

#### Deferred financing costs

Deferred financing costs represent fees and other direct incremental costs incurred in connection with the Company's borrowings. These amounts are amortized and included in interest expense in the consolidated statements of operations over the estimated average life of the borrowings.

As of March 31, 2015 and 2014, the Company had no deferred financing costs, respectively.

### Amortization expense

For the quarter ended March 31, 2015 and 2014 the Company had no amortization costs, respectively.

#### Deferred offering costs

Deferred offering costs consist of fees paid in relation to legal, accounting, regulatory and printing work completed in preparation of equity offerings. Deferred offering costs are charged against the proceeds from equity offerings when received. As of March 31, 2015 and 2014, the Company had no deferred offering costs, respectively.

#### Stock-based compensation

The Company accounts for stock-based awards to employees using the fair value based method to determine compensation for all arrangements where shares of stock or equity instruments are issued for compensation.

In addition, the Company accounts for stock-based compensation to nonemployees in accordance with the accounting guidance for equity instruments that are issued to others than employees.

For the quarter ended March 31, 2015 and 2014, the Company did not issue any stock options in lieu of cash as employee compensation.

For the quarter ended March 31, 2015, the Company issued stock in lieu of cash for legal services provided to the Company's SEC counsel at the price of \$.15 per share, which was the prevailing price of the stock listed on the OTC Pink Market exchange at the time that the shares were issued.

In the future, the Company intends to use a similar option pricing model to the Black-Scholes optionpricing model to determine the fair value of each option grant as of the date of grant for expense incurred. The Black-Scholes model requires inputs for risk-free interest rate, dividend yield, expected stock price volatility and expected life of the options. Expected stock price volatility is based on historical volatility of the Company's stock and the stock of the Company's peer companies. The risk-free interest rate for periods within the contractual life of the option is based on the U.S. Treasury yield curve in effect at the time of the grant. The expected life for options granted represents the period of time that options granted are expected to be outstanding and is derived from the contractual terms of the options granted.

#### Income taxes

Income taxes are accounted for using the asset and liability approach in accordance with FASB Topic 740, Income Taxes ("ASC 740"). Deferred tax assets and liabilities reflect the impact of temporary differences between the carrying amount of assets and liabilities and their tax basis and are stated at tax rates expected to be in effect when taxes are actually paid or recovered. Deferred tax assets are also recorded for net operating losses, capital losses and any tax credit carryforwards. A valuation allowance is provided against a deferred tax asset when it is more likely than not that some or all of the deferred tax assets will not be realized. All available evidence, both positive and negative, is considered to determine whether a valuation allowance for deferred tax assets is needed. Items considered in determining our valuation allowance include expectations of future earnings of the appropriate tax character, recent historical financial results, tax planning strategies, the length of statutory carryforward periods and the expected timing of the reversal of temporary differences. Under ASC 740, forming a conclusion that a valuation allowance is not needed is difficult when there is negative evidence, such as cumulative losses in recent years.

The Company recognizes tax benefits of uncertain tax positions only when the position is more likely than not to be sustained assuming examination by tax authorities. We record income tax related interest and penalties, if applicable, within current income tax expense.

#### **Recent accounting pronouncements**

In June 2013, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2013-08, Financial Services — Investment Companies (Topic 946): Amendments to the Scope, Measurement and Disclosure Requirements ("ASU 2013-08"), containing new guidance on assessing whether an entity is an investment company, requiring non-controlling ownership interest in investment companies to be measured at fair value and requiring certain additional disclosures. This guidance is effective for annual and interim periods beginning on or after December 15, 2013. The Company does not expect ASU 2013-08 to have a material impact on the Company's consolidated financial position or disclosures.

#### Note 3. Related Party Transactions

In 2013, the Company purchased common stock and membership interests in two corporations with a combined market value of \$457,500 from AmeriFinancial and Kerri Parsons. These-corporations are Active Faith, Inc. and Thru Pharma, LLC. Steven Morgan and Kerri Parsons hold officer positions in both AmeriFinancial and Champion Investments. The purchase price of the common stock and membership interest was paid in common stock shares of the Company in lieu of cash.

During the quarter ended March 31, 2015 no salaries, wages, shares of stock or fees were paid by the Company to Steven C. Morgan, as Managing Director of AmeriFinancial or as Chairman and Chief Executive Officer of Champion Investments Inc. Mr. Morgan did receive compensation of \$60,000 in June 2014 as payment for serving as Chairman and CEO of the Company since his election in April 2009 through December 2012.

#### **Related Party Loan Transactions.**

During the period May 2009 through December 31, 2012, the Company was funded on a periodic and as needed basis by AmeriFinancial. The total amount of funding by AmeriFinancial to Champion Investments, Inc, through March 31, 2014 had been \$29,157. This loan had interest payments in 2014 calculated at a 5% interest rate and was paid in full on its maturity date of May 30, 2014.

#### Note 4. Earnings (Loss) Per Share

	Quarter Ended March 31	
	2015	2014
Loss Per Share Basic and Diluted	(\$18,060)	(\$31,812)
Denominator for basic and diluted weighted average shares: Basic and diluted earnings (loss) per share	75,307,167 (\$0.00)	75,181,167 (\$0.00)

In accordance with the provisions of FASB ASC Topic 260, *Earnings per Share*, basic earnings per share ("EPS") is computed by dividing earnings available to common shareholders by the weighted average number of shares outstanding during the period. Other potentially dilutive common shares, and the related impact to earnings, are considered when calculating EPS on a diluted basis. In computing diluted EPS, only potential common shares that are dilutive, those that reduce earnings per share or increase loss per share, are included. The effect of stock options, unvested employee stock awards and contingently issuable shares are not included if the result would be anti-dilutive.

#### Note 5. Investments

The following fair value hierarchy set for the Company's assets that are measured at fair value on a recurring basis by level as of March 31, 2015 and 2014.

#### Period Ended March 31, 2015

	Level 1	Level 2	Level 3	Total
Convertible Debt	\$0	\$0	\$8,000	\$8,000
Equity Common	0	0	0	0
Equity	0	0	321,000	321,000
Structured Products	0	0	0	0
Total	\$0	\$0	\$329,000	\$329,000

#### Period Ended March 31, 2014

	Level 1	Level 2	Level 3	Total
Convertible Debt Preferred	\$0	\$0	\$0	\$0
Equity	0	0	0	0
Common Equity	0	0	457,500	457,500
Structured Products	0	0	0	0
Total	\$0	\$0	\$457,500	\$457,500

The following table shows the components of change in the Company's investments categorized as Level 3, for the period ended March 31, 2015.

#### Fair Value Measurements Using Significant Unobservable Inputs (Level 3) \*\*

	Common/Equity Interests	Convertible debt
Beginning Balance December 31, 2014	<b>\$</b> 457,500	\$8,000
Total Realized Gains (Losses) included in Earnings	0	0
Total Change in Unrealized Depreciation or Appreciation included in Earnings	136,500	0
Net Amortization on Investments	0	0
Purchases	0	0
Sales	0	0
Ending Balance March 31, 2015	\$321,000	\$8,000

\*\* Pursuant to fair value measurement and disclosure guidance, the Company currently categorizes investment by class as shown above.

#### Note 6. Borrowings

In accordance with the 1940 Act, with certain limited exceptions, the Company is only allowed to borrow amounts such that its asset coverage, as defined in the 1940 Act, is at least 200% after such borrowing. As of March 31, 2015, the Company's asset coverage for borrowed amounts far exceeded the 200% threshold.

#### Note 7. Federal Income Tax Matters

For the quarters ended March 31, 2015 and 2014, respectively, the Company had a net loss of \$18,060 and \$31,812, respectively. As a result, no Federal or Texas State Franchise taxes were due and payable. Accordingly, no provision for federal income tax was made in the financial statements for periods ending March 31, 2015 and 2014, respectively.

In assessing the reliability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future results of operations and tax planning strategies in making this assessment. Based upon the level of historical tax income, significant book losses during the current and prior periods and projections for future results of operations over the periods in which the deferred tax assets are deductible, among other factors, management concluded that, at this time, that the Company did not meet the "more likely than not" requirement in ASC 740 in order to recognize deferred tax assets and a valuation allowance has been recorded for the full amount of our net deferred tax assets at March 31, 2015 and 2014.

During the period from March 31, 2015 and thereafter, the Company will continue to assess the realizability of our deferred tax assets based on consideration of actual and projected operating results and tax planning strategies. Should actual operations improve, the amount of the deferred tax asset considered more likely than not to be realizable could be increased.

Income tax expense was different from the amounts computed by applying U.S. Federal income tax of 35% to pretax income as a result of the following:

	Quarter Ended March 31	
	2015	2014
Federal statutory rate	35.0%	35.0%
Less valuation allowance	-35.0%	-35.0%
Effective income tax rate	0%	0%

Deferred tax assets are comprised of the following at March 31, 2015:

	Quarter Ended March 31	
Deferred Tax Assets	2015	2014
Net operating loss carryforwards	\$3,179,772	\$3,080,380
Less: valuation allowances	(3,179,772)	(3,080,380)
Net deferred tax assets	\$0	\$0

The Company has net operating loss carryovers as of December 31, 2014 in the amount of \$9,033,462 for Federal income tax purposes. If not utilized, the tax net operating loss carryforwards will expire during 2025 through 2034.

Due to this tax loss carry forward, the Company has not elected to be treated as a RIC under Subchapter M of the Code regarding its status as a business development company, and as a result will not be obligated to distribute substantially all of its respective net taxable income to its shareholders.

#### Note 8. Commitments and Contingencies

#### Commitments

The Company had no outstanding commitments to fund investments as of March 31, 2015 or 2014, respectively.

#### Indemnifications

In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties that provide general indemnifications. The Company's maximum exposure under these arrangements is unknown, as these involve future claims that may be made against the Company but that have not occurred. The Company expects the risk of any future obligations under these indemnifications to be remote.

#### Off-balance sheet risk

Off-balance sheet risk refers to an unrecorded potential liability that may result in a future obligation or loss, even though it does not appear on the statements of financial condition.

The Company had no outstanding unrecorded potential liability that may result in a future obligation or loss, as of March 31, 2015 and 2014, respectively.

#### Legal proceedings

In the normal course of business, the Company may be subject to legal and regulatory proceedings that are generally incidental to its ongoing operations. While there can be no assurance of the ultimate disposition of any such proceedings, the Company does not believe any disposition will have a material adverse effect on the Company's consolidated financial statements.

As of March 31, 2015 the Company was not subject to any legal proceedings or claims.

#### Note 9. Equity

#### Common stock

During the quarter ended March 31, 2014, the Company sold in a private placement 500,000 shares for cash proceeds totaling \$50,000. During the quarter ended March 31, 2015, the Company issued an additional 10,000 shares of common stock for legal services provided by the Company's SEC counsel. The fair value of these shares was \$0.15 each at the time that they were approved for issue.

#### Stock Options

On April 30, 2009, the current management of the Company granted stock options to two individuals for the purchase of 500,000 shares each of the Company's common stock at the option price of \$.10 per share, which was the current price of the stock at the time of issuance of these options. These options were granted for settlement of an outstanding invoice for consulting fees in the amount of \$100,000 from

the year 2011. As of January 1, 2014, these options were fully vested and expired as they had not been exercised by their expiration date on April 30<sup>th</sup>, 2014.

#### Note 10. Subsequent Events

There are no subsequent events to report after quarter end to the date of filing this report.

#### PART III

#### Item 10. Directors, Executive Officers and Corporate Governance

The following is a listing of the Officers and Directors and outside providers for the Company

Executive Name	<u>Age</u>	Position_	
Steven C. Morgan	67	Chairman, Chief Executive Officer	
Desmonde C.A. Cowdery	61	Chief Financial Officer & Chief Compliance Officer	
Kerri G. Parsons, PhD	54	Vice President, Investor Relations	
Robert F. Hill	67	Independent Board Director	
Marion P. Wright	63	Independent Board Director	

#### Chairman and Chief Executive Officer, Steven C. Morgan

Mr. Steven C. Morgan has been the Chairman and Chief Executive Officer of the Company since April 2009. Mr. Morgan has occupied these positions upon the installation of new management in 2009. During this period, Mr. Morgan has been directly involved in the total restructuring of the Company to include its current business model, capital structure and financial condition.

During his career, as principal, investor or agent, Mr. Morgan has been responsible for the development, operations or financing of more than 60 different companies in the technology, medical, manufacturing, energy, food, retail, hospitality, construction and real estate industries.

From 1995 to the present, Mr. Morgan has also been the Founder and Managing Director of AmeriFinancial, LLC, an organization that specializes in providing emerging organizations advisory services with regard to business model development, financial modeling, executive recruiting and capital raising efforts. Prior to founding AmeriFinancial, from 1978-1993, Mr. Morgan was the Founder, Chairman and Chief Executive Officer of Hospitality Investments, Inc., an operating hospitality and real estate organization with approximately 350 employees.

Prior to this, Mr. Morgan was selected as the youngest Vice President in the history of Servico, a publicly held entity specializing in acquiring, developing and operating hotels across the United States. In this capacity, Mr. Morgan was responsible for all union and non-union hotel operations in the Northeast

section of the United States with locations in New York City, Connecticut and Pennsylvania. He was also held accountable for the direct oversight of the Company's premiere flagship hotel and brand.

Mr. Morgan received his business degree from Washington University in Saint Louis, Missouri and his MBA degree from the University of Cincinnati.

#### Chief Financial Officer/Chief Compliance Officer, Desmonde Cowdery

Mr. Cowdery has over 30 years of financial management experience in both public and private companies including financial management of private equity backed businesses, entrepreneurial and emerging growth companies and international multi-location public companies.

From 2006 to 2012, Mr. Cowdery was the Chief Financial Officer for Wilson-Mohr Inc., a multi-location value-added distributor of industrial control and automation equipment. Under his financial leadership, the firm's annual sales expanded from \$15 million to over \$60 million.

From 2001 to 2006 and 2012 to 2014, Mr. Cowdery, was Founder and President of DNR Associates, a strategic CFO consultancy that specialized in assisting enterprises in their transitional change periods, which included high growth situations, mergers, acquisitions and turnaround situations.

Previous to this, from 1988 to 2001, Mr. Cowdery held CFO positions for a regional homebuilder, international oilfield drilling services organization an early-stage entity that was developing innovative microscopic identification, security and marking products for liquid processing industries and a subsidiary of a London-based FTSE-100 public corporation.

Mr. Cowdery is a member of the Institute of Chartered Accountants in England & Wales (ACA) and received his MBA degree from the University of Houston,

#### Vice President, Investor Relations, Kerri Parsons, PhD

Dr. Kerri Parsons is the Vice President, Investor Relations of the Company.

Dr. Parsons is a highly accomplished executive with more than a decade of demonstrated senior management experience in diverse sectors including venture capital, consulting, non-profit organizations, gerontology, developmental neuropsychology and academia. With the establishment of Champion Investments, Inc. in 2009, Dr. Parsons has served as an integral part of the Company's core development, unique business model and investor relations programs

Since 2007, Dr. Parsons has been the Vice President of AmeriFinancial, LLC, a private investment and venture capital advisory firm with offices in Houston and Fort Worth, Texas. Her responsibilities include working with start-up or early-stage entrepreneurs to fully develop and accurately document their plans, business models and operating strategies, as well as their fundraising activities. Dr. Parsons has played a key role in the development and growth of the life sciences division of the Company.

As a Company executive team member, Dr. Parsons is responsible for the creation, implementation and management for all of the Company's investor relations, including communications media, advertising, internal publications and public relation functions. She will also be held accountable for information given to the financial community.

#### **Non-Executive Officer Management**

#### Independent Board Director, Marion Wright

Mr. Wright brings over 40 years of experience with both major and independent oil companies in a career that covered much of the world including onshore and offshore assignments on six continents.

Mr. Wright began his career with Shell Oil Company where he advanced through various domestic and international technical and management assignments with increasing responsibility. He later worked for Pennzoil where he was Director of International Engineering & Operations followed by De von Energy, ExxonMobil CIS and Chevron North America.

Currently, Mr. Wright serves as a Senior Executive for Texas Petroleum Investment Company based in Houston, Texas. He manages Eastern Division development and exploration, all corporate reserve reporting, business analysis and budgeting and advises on acquisitions and divestitures for the firm

Mr. Wright sits as an Independent Director on the Company's Board of Directors and contributes to the Compensation and Investment Committees of the Company.

#### Non-Executive Key Management

#### Independent Board Director, Robert F. Hill

Mr. Hill has over 30 years of financial and operational experience in the construction, agricultural and food related industries. Mr. Hill oversees all accounting and administration for Champion.

In 1998, Mr. Hill founded Integrated Solutions, a business consultancy that specializes in financial management, tactical planning and core growth strategies for numerous clients in the construction, agriculture, food processing and financial service industries. Since its inception, Mr. Hill has been directly involved in providing financial assistance to over 20 early stage, emerging or small business enterprises.

Prior to the establishment of his consultancy business, Mr. Hill was a senior accountant for Ernst & Young, where he was responsible for the management of the accounting in the agricultural industry.

#### **Other Matters**

#### Outside providers

The following is a list of the outside providers for the Company as of September 30, 2014.

#### General Counsel

Jerry Walker, Jr., 5850 San Felipe, Houston, TX 77057 Telephone: 713.706.6101, email address: jwalkerjr@gmail.com Tel: (832)617-5683

#### SEC Counsel

Daniel Kirshbaum 4900 Woodway, Suite 600, Houston, Texas 77056 Telephone: 832.617.5683, email address: drkirshbaum@aol.com

#### Auditors

GBH CPAs P.C., David A. Grossman, CPA, 6002 Rogerdale, Suite 500 Houston, Texas 77072 Telephone: 713.482.0000, e-mail address: dgrossman@gbhcpas.com

#### Stock Transfer Agent

Salli Marinov, First American Stock Transfer, Inc., 4747 North 7<sup>th</sup> Street, Phoenix, Arizona 85014 Telephone: 713.622.2310, email address: <u>smarinov@fast.com</u>

#### Item 11. Executive Compensation

#### **Employment agreements and letters of intent**

As of March 31, 2015, the Company had certain compensation agreements with each Corporate Officer. These agreements include shares of common stock that may be issued in addition to salaries as incentives to the Officers of the Company. These common stock shares are granted in connection with certain officers' initial engagement agreements, which could result in up to 4,225,000 shares of common stock being granted in the future among these individuals, if certain milestones are met and achieved by the Company.

During the quarter ending March 31, 2015, there were no salaries or wages paid to any officer of the Company.

#### **Board of Director Compensation**

During the quarter ended March 31, 2015 and 2014, Mr. Morgan did not receive any compensation for serving as the Chairman of the Board and Chief Executive Officer of the Company.

During the quarter ended March 31, 2015 and 2014, Mr. Wright did not receive any compensation for serving as an Independent Board Director.

During the quarter ended March 31, 2015 and 2014, Mr. Hill did not receive any compensation for serving as an Independent Board Director.

#### Item 12. Security Ownership of Beneficial Owners and Management and Related Stockholder Matters

There were 75,307,167 shares issued and outstanding with current shareholders listed below as of March 31, 2015.

	Relationship to	Shares	%
	<u>Company</u>	<u>Owned</u>	<u>Owned</u>
AmeriFinancial	1	40,365,000	53.6
Ronald Parsons	None	10,000,000	13.3
AG IR Garland Holdings LP	None	3,474,618	4.6
Joseph & Judith Simpson	None	3,146,000	4.2
Marion Wright	4	4,450,000	5.9
Kathleen Cullen	None	1,524,000	2.0
Jerry Walker	2	1,512,500	2.0
Cynthia Walker	3	1,512,500	2.0
Jerre Maxwell	None	1,250,000	1.7
Bridget Heinrich	None	1,240,000	1.6
Timothy Karney	None	1,199,000	1.6
All others	None	5,633,549	7.5
TOTAL		75,307,167	100%

- (1) AmeriFinancial, LLC is owned by family shareholders of Steven C. Morgan, the Chairman and Chief Executive Officer of the Company.
- (2) Jerry Walker, Jr. is a legal Advisor for the Company.
- (3) Cynthia Walker is a family shareholder of Jerry Walker, Jr.
- (4) Marion Wright is an Independent Director on the Champion Investments Board of Directors.

#### Part IV.

#### Item 13. Certain Relationships and Related Transactions, and Director Independence

Steven Morgan is the Chairman and Chief Executive Officer of Champion Investments, Inc. Mr. Morgan is also the Managing Director of AmeriFinancial, which holds 40.365 million common stock shares of Champion Investments, Inc.

Dr. Kerri Parson is Vice President, Investor Relations of Champion Investments, Inc. Dr. Parsons is also the Vice President, Senior Associate of AmeriFinancial, which holds 40.365 million common stock shares of Champion Investments, Inc. Kerri Parsons holds 335,000 shares of common stock in Champion Investments, Inc., which is less than 1% of the shares outstanding.

Marion P. Wright has been an Independent Director on the Board of Directors of Champion Investments, Inc. since December 2013. Mr. Wright holds 4.45 million shares of common stock in Champion Investments, Inc., which represents 5.9% of the shares outstanding. Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this Annual Report on Form 10-K to be signed on its behalf by the undersigned, thereunto duly authorized.

Champion Investments, Inc. A Nevada Corporation Registrant

By:

SenderMo

Name: Steven C. Morgan Title: Chairman, Chief Executive Officer April 5, 2015

